61 It exhibited a dose-dependent increase in intracellular cAMP levels in CHO cells expressing the human GLP-1 receptor
4.1 Approved products and emerging TME-oriented candidates Approved nanomedicines in oncology are still dominated by formulations centered on exposure modification, with limited explicit TME remodeling
Major US medical organizations including ACOG, The Menopause Society, and NASEM have concluded that compounded bioidentical hormone therapy claims of superior safety or effectiveness over FDA-approved hormone therapy are not substantiated by evidence from well-designed clinical studies, and that FDA-approved hormone therapy products are generally recommended over compounded alternatives when an FDA-approved formulation appropriate to the patient is available
GLP-1 drugs reduced kidney failure by 16% and major heart events by 13% across all studies.5 THE BOTTOM LINE GLP-1 medications are now considered a fourth pillar of kidney protection for people with type 2 diabetes, alongside blood pressure drugs, SGLT2 inhibitors, and finerenone
Healthy weight loss is rarely a straight line, and temporary plateaus are common during treatment